Evidence map›Paper›PMID 34764413›Full record

ArticleCommunications biology2021

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.

Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nobuyuki ShimizuDepartment of Chemical Biology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Tomoko Asatsuma-OkumuraDepartment of Chemical Biology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.ORCID http://orcid.org/0000-0002-9629-6795
Junichi YamamotoSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Yuki YamaguchiSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Hiroshi HandaDepartment of Chemical Biology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. hhanda@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0001-6656-9521
Takumi ItoDepartment of Chemical Biology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. takumii@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0002-9997-2664
Tokyo Medical University · JPTokyo Institute of Technology · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 17H06112MEXT | Japan Society for the Promotion of Science (JSPS) 18H05502MEXT | Japan Society for the Promotion of Science (JSPS) 19K16378MEXT | Japan Society for the Promotion of Science (JSPS) 20K08741MEXT | Japan Society for the Promotion of Science (JSPS) 20K16314
6 · The paper itself

Abstract

Pomalidomide and lenalidomide are immunomodulatory agents that were derived from thalidomide. Cereblon (CRBN) is a common direct target of thalidomide and related compounds and works as a Cullin Ring 4 E3 ubiquitin ligase (CRL4) with DDB1, CUL4, and ROC1. The substrate specificity of CRL4

Indexed as

Adaptor Proteins, Signal TransducingAmino Acid SequenceHEK293 CellsHumansPromyelocytic Leukemia Zinc Finger ProteinSequence AlignmentThalidomideUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCRBN protein, humanpomalidomidePromyelocytic Leukemia Zinc Finger ProteinThalidomideUbiquitin-Protein LigasesZBTB16 protein, human

Identifiers

PMID34764413
PMCPMC8586336
OpenAlexW3212657068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.